Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Irinotecan Dose Adjustment Guided by UGT1A1*6 Genotype in VIT Regimen for the Treatment of Relapsed and Refractory Childhood Solid Tumors

NCT06760117 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06760117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06760117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Irinotecan Dose Adjustment Guided by UGT1A1*6 Genotype in VIT Regimen for the Treatment of Relapsed and Refractory Childhood Solid Tumors
Lead sponsor
Sun Yat-sen University
Phase
Phase 1
Overall status
Recruiting
Start date
January 1, 2022
Completion date
December 31, 2025
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric solid tumor